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Abstract
Background: A role for vitamin D in cancer risk reduction has been hypothesized, but few data exist for lung cancer. We
investigated the relationship between vitamin D status, using circulating 25-hydroxyvitamin D [25(OH)D], and lung cancer
risk in a nested case-control study within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study of Finnish male
smokers.
Methods: Lung cancer cases (n=500) were randomly selected based on month of blood collection, and 500 controls were
matched to them based on age and blood collection date. Odds ratios (ORs) and 95% confidence intervals (CIs) were
calculated using multivariate-adjusted conditional logistic regression. To account for seasonal variation in 25(OH)D
concentrations, season-specific and season-standardized quintiles of 25(OH)D were examined, and models were also
stratified on season of blood collection (darker season=November–April and sunnier season=May–October). Pre-
determined, clinically-defined cutpoints for 25(OH)D and 25(OH)D as a continuous measure were also examined.
Results: Overall, 25(OH)D was not associated with lung cancer. Risks were 1.08 (95% CI 0.67–1.75) and 0.83 (95% CI 0.53–
1.31) in the highest vs. lowest season-specific and season-standardized quintiles of 25(OH)D, respectively, and 0.91 (95% CI
0.48–1.72) for the $75 vs. ,25 nmol/L clinical categories. Inverse associations were, however, suggested for subjects with
blood collections from November–April, with ORs of 0.77 (95% CI 0.41–1.45, p-trend=0.05) and 0.65 (95% CI 0.37–1.14, p-
trend=0.07) in the highest vs. lowest season-specific and season-standardized quintiles of 25(OH)D, respectively, and 0.61
(95% CI 0.24–1.52, p-trend=0.01) for $75 vs. ,25 nmol/L. We also found 11% lower risk for a 10 nmol/L increase in
25(OH)D in the darker season based on the continuous measure (OR=0.89, 95% CI 0.81–0.98, p=0.02).
Conclusion: In this prospective study of male smokers, circulating 25(OH)D was not associated with lung cancer risk overall,
although inverse associations were suggested among those whose blood was drawn during darker months.
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Introduction
Higher vitamin D intake or status has been hypothesized to
be associated with reduced risk of several cancers, including
colorectal, breast, and prostate [1,2]; however, few studies have
examined the association between vitamin D status and risk of
lung cancer. Circulating 25-hydroxyvitamin D [25(OH)D], the
accepted biomarker of vitamin D status, was not associated
with lung cancer mortality in an analysis of the National
Health and Nutrition Examination Survey (NHANES) [3], but
in a recent reanalysis of the NHANES data, incorporating
more cases and longer follow-up, higher 25(OH)D was
significantly associated with increased lung cancer mortality
in men [4]. Serum 25(OH)D was not associated with lung
cancer incidence overall in a Finnish cohort study [5], although
inverse associations were observed among women and those
younger than 50 years [5].
In order to examine the association between circulating vitamin
D and lung cancer risk, we conducted a nested case-control study
within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention
(ATBC) Study cohort of male smokers in Finland (latitude of study
area 60–64uN) with 500 lung cancer cases and up to 20 years of
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20796follow-up. Multiple approaches were used to address seasonal
variation in 25(OH)D concentrations.
Methods
Ethics statement
The study was approved by the institutional review boards of
the U.S. National Cancer Institute and the National Public Health
Institute of Finland, with written informed consent obtained from
each participant.
Study population
The overall design, rationale, and objectives of the ATBC Study
have been published [6].
The Study was a randomized, double-blind, placebo-controlled,
primary prevention trial with daily supplementation of a-
tocopherol (50 mg/day), b-carotene (20 mg/day), both, or
placebo. Participants (n=29,133) aged 50–69 years, who smoked
at least five cigarettes per day, were recruited from southwestern
Finland from 1985–1988. Study supplementation continued for 5–
8 years (median 6.1 years) until death or trial closure (April 30,
1993).
Case identification and control selection
Incident lung cancer cases (n=500) were randomly selected
from among 2,948 eligible cases (International Classification of
Diseases 9, code 162) diagnosed through April 30, 2005. The cases
were identified through the Finnish Cancer Registry, which
provides nearly 100% case ascertainment [7]. Based on month of
baseline blood collection, 50 cases were randomly selected from
each month, with 50 cases total selected from June–August since
there were few summer blood collections. For cases diagnosed
through April 1999 (n=318), one or two study physicians
reviewed medical records for diagnostic confirmation and staging.
Cases diagnosed since May 1999 (n=182) had only the Finnish
Cancer Registry data for site, histology, and date of diagnosis.
Histology data were available for all but 87 cases. The main
histologic subtypes were small cell carcinoma (n=100), squamous
cell carcinoma (n=179), and adenocarcinoma (n=73), defined by
International Classifications of Diseases for Oncology, 2
nd edition,
codes of 80413–80493, 80702–80708, and 81403–82508, respec-
tively. Controls were alive and cancer-free at the time of case
diagnosis and matched to cases (1:1) on age at randomization (+/
21 year) and date of baseline serum collection (+/230 days).
Serum 25-hydroxyvitamin D determination
Fasting serum samples were collected at baseline and stored at
270uC. 25(OH)D was measured at Heartland Assays, Inc. (Ames,
IA) with the DiaSorin Liaison 25(OH)D TOTAL assay platform
using a direct, competitive chemiluminescence immunoassay [8,9].
Each batch contained matched case/control sets and blinded
quality control samples, comprising 5% of the total sample number.
Intrabatch and interbatch coefficients of variation were calculated
using a nested components of variance analysis [10], and ranged
between 9.3%–11.0% and 12.3%–13.6%, respectively.
Statistical analysis
Case and control characteristics were compared using Wilcoxon
rank sum or chi-square tests. Correlations were determined among
controls using Spearman’s rank order coefficient. Odds ratios (OR)
and 95% confidence intervals (CI) were calculated using
conditional logistic regression. To account for seasonal variation
in 25(OH)D concentrations, season-specific and season-standard-
ized quintiles of 25(OH)D were created, and models for each
25(OH)D classification were stratified on season of blood
collection. The season-specific 25(OH)D quintiles were created
based on month of blood collection (‘‘darker months’’=Novem-
ber–April and ‘‘sunnier months’’=May–October). The season-
standardized quintiles were created from the residuals from a
model regressing log transformed 25(OH)D against calendar week
of blood collection [9]. Pre-defined cutpoints for 25(OH)D, based
on clinical definitions in the literature [11–13], were also
examined. The cutpoints were ,25, 25 to ,37.5, 37.5 to ,50,
50 to ,75 (referent category), and $75 nmol/L. The referent
category was chosen to mirror that used in other studies of
circulating 25(OH)D and cancer [9,14,15]; it includes the mean
concentration of the US population [16], and reflects sufficiency as
recently defined by the Institute of Medicine [17]. This allows for
calculation of risk estimates at high and low 25(OH)D concentra-
tions compared to subjects with a ‘‘sufficient’’ 25(OH)D
concentration. We also included risk estimates using the lowest
pre-defined category as the referent. Tests for linear trend were
obtained by assigning to each category an ordinal value (1–5) and
treating this parameter as a continuous variable. 25(OH)D was
also modeled as a continuous variable, based on a 10 nmol/L
change in the original concentration and a one-residual unit
change in the season-standardized classification; results using a
log-transformed continuous variable were nearly identical to the
latter and are not shown.
Factors tested as confounders included age, height, weight, body
mass index, number of cigarettes smoked per day, years and pack-
years of smoking, education, physical activity, family history of
lung cancer, alcohol intake; serum b-carotene, a-tocopherol,
retinol, and cholesterol; and the trial supplementation. We did not
consider vitamin D intake or supplement use as these would be
direct determinants of 25(OH)D. None of the aforementioned
factors changed the 25(OH)D coefficients by more than 10% when
added to the univariate models. However, we present a
multivariate model adjusted for common lung cancer risk factors,
including smoking (cigarettes/day and years smoked, both
continuous), body mass index (continuous), serum cholesterol
(continuous), trial supplementation (a-tocopherol yes/no, b-
carotene yes/no), and alcohol intake (categorical with separate
categories for non-drinkers and those with missing data).
Subgroup analyses stratified on median age, body mass index,
cigarettes/day, years smoked, alcohol intake, vitamin D intake;
serum a-tocopherol, b-carotene, retinol and cholesterol; leisure
physical activity (moderate and heavy vs. sedentary) and trial
supplementation, were conducted using unconditional logistic
regression, adjusting for the matching factors. The season-specific
25(OH)D measure was used, split at quintiles 4–5 vs. quintiles 1–3.
Models stratified on follow-up time (,10 years and $10 years),
stage (1–2 vs. 3–4), and histology (small cell carcinoma, squamous
cell carcinoma, and adenocarcinoma), were run conditionally.
Effect modification was statistically evaluated by comparing
models with and without a cross-product interaction term
(25(OH)D crossed with the effect modifier) using the log-likelihood
ratio test. Statistical analyses were performed using SAS software
version 9.1.3 (SAS Institute, Inc., Cary, North Carolina) and all P-
values were 2-sided.
Results
Lung cancer cases smoked more cigarettes for a longer period of
time, had lower body mass index and education, were more
sedentary, and more likely to have a family history of lung cancer
than controls. Cases also had lower baseline concentrations of
serum b-carotene, retinol, and a-tocopherol; and higher alcohol
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significantly correlated with body mass index (r=0.11); serum
cholesterol (r=20.10), retinol (r=0.11) and a-tocopherol
(r=0.14); and intakes of vitamin D (r=0.33), fish (r=0.34), milk
(r=20.24), and alcohol (r=0.15) (all p,0.02). Serum 25(OH)D
was not correlated with smoking: r=20.02, p=0.73 for total
cigarettes/day; r=20.04, p=0.40 for years of smoking; and
r=20.05, p=0.28 for pack-years of smoking.
Regardless of approach to seasonal variation in vitamin D
status, serum 25(OH)D was not associated with lung cancer risk
overall. For example, multivariate-adjusted risks in the highest vs.
lowest quintile were 1.08 (95% CI 0.67–1.75) and 0.83 (95% CI
0.53–1.31) using the season-specific and season-standardized
25(OH)D measures, respectively (Table 2). Compared to the
referent category of 50–,75 nmol/L, neither high ($75 nmol/L)
nor low (,25 nmol/L) 25(OH)D concentrations were associated
with lung cancer risk (Table 2), and there was no difference in risk
between the highest and lowest categories (OR=0.91, 95% CI
0.48–1.72 for $75 vs. ,25 nmol/L). The multivariate-adjusted
risks using a continuous 25(OH)D measure were 0.98 (95% CI
0.91–1.05, p=0.35) for a 10 nmol/L change in 25(OH)D
concentration and 0.84 (95% CI 0.66–1.07, p=0.17) for a 1-
unit change in the season-standardized residual.
In contrast to the overall findings, we observed inverse
associations in men whose blood was collected during the darker
season of the year. Trend test p-values were 0.05 (season-specific
measure), 0.07 (season-standardized measure) and 0.01 (pre-
determined cutpoints)(Table 2). The individual category risk
estimates and interaction tests were not statistically significant,
however. The odds ratios comparing the highest ($75 nmol/L) vs.
lowest (,25 nmol/L) pre-defined vitamin D categories by season
were 0.61 (95% CI 0.24–1.52) and 1.90 (95% CI 0.67–5.42) for
darker and sunnier seasons, respectively. The inverse pattern in
the darker season was also supported by the continuous 25(OH)D
Table 1. Selected baseline characteristics of cases and controls,
1 Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study.
Characteristic Cases, n=500 Controls, n=500 P
2
Age (y) 59 (55–62) 59 (55–62) matched
Body mass index (kg/m
2) 25.4 (22.9–27.9) 25.8 (23.6–28.1) 0.02
Blood collection in darker months (Nov–April) 60.0% 58.4% matched
Cigarettes smoked/day 20 (20–30) 20 (15–25) ,0.0001
3
Years smoked 40 (35–44) 38 (32–43) ,0.0001
Pack-years of smoking 42 (34–54) 34 (23–45) ,0.0001
Positive family history of lung cancer
4 13.9% 7.4% 0.01
Education (%.elementary) 16.0% 22.0% 0.02
Physical activity in leisure 0.05
Sedentary 43.0% 38.6%
Moderate 53.0% 54.4%
Heavy 3.8% 7.0%
Dietary intake/day
5
Energy (kcal) 2547 (2120–3116) 2621 (2180–2999) 0.86
Vitamin D (mg) 4.8 (3.2–6.8) 4.7 (3.4–6.7) 0.73
Calcium (mg) 1318 (1011–1674) 1333 (1019–1697) 0.91
Fish (g) 32.4 (18.1–51.4) 32.7 (19.5–51.3) 0.42
Milk (g) 24.3 (0.0–460.0) 24.3 (0.0–460.0) 0.87
Alcohol (g of ethanol) 10.7 (1.8–26.1) 8.0 (1.6–20.8) 0.04
Dietary supplement use (%yes)
6
Vitamin D 7.8% 6.8% 0.36
Calcium 11.8% 10.4% 0.21
Serum concentrations
25(OH)D (nmol/L) 33.6 (20.7–50.2) 35.0 (21.5–50.5) 0.33
b-Carotene (mg/L) 165 (102–249) 190 (127–304) ,0.0001
Cholesterol (mmol/L) 6.1 (5.4–6.9) 6.2 (5.5–7.0) 0.10
Retinol (mg/L) 560 (473–650) 575 (509–670) 0.002
a-Tocopherol (mg/L) 11.3 (9.6–13.3) 11.6 (10.2–13.7) 0.02
1All values are medians and interquartile ranges unless otherwise indicated as percentages.
2P-values are based on Chi-square tests (for categorical variables) and Wilcoxon rank sum tests (for continuous variables).
3Median values for number of cigarettes per day are identical because 31% of subjects reported smoking a pack of cigarettes/day (=20), however, the overall
distributions by case/control status differ, as is evident by the interquartile ranges and the p-value.
4Family history data available for 67.6% of subjects.
5Dietary data available for 94.2% of subjects.
6Only 21.2% of subjects reported any supplement use.
doi:10.1371/journal.pone.0020796.t001
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0.81–0.98, p=0.02) for the darker season and 1.07 (95% CI
0.95–1.21, p=0.25) for the sunnier season, for a 10 nmol/L
change in 25(OH)D concentration, p-interaction 0.01, and 0.67
(95% CI 0.50–0.90, p=0.01) for the darker season and 1.36 (95%
CI 0.82–2.27, p=0.23) for the sunnier season, for a 1-unit change
in the season-standardized residual, p-interaction 0.04.
Analysis of selected subgroups (Table S1) showed lower risks for
participants with higher serum 25(OH)D who had above median
dietary and total vitamin D intake, alcohol intake, serum a-
tocopherol, or body mass index, and those with below median
serum b-carotene. Suggested risk elevations were noted for
subjects in the placebo group of the trial supplementation
(compared with the other supplementation groups), and those
with small cell lung cancer (compared with squamous cell
carcinoma or adenocarcinoma). None of the interactions were
statistically significant, however, and no differences were noted in
subgroups of disease stage, follow-up time, smoking characteristics,
physical activity, or the other factors tested.
Discussion
Circulating 25(OH)D was not associated with lung cancer risk
overall in this study; however, inverse associations were suggested
for subjects whose blood was collected in the darker months. The
patterns were similar using pre-defined, season-specific, and
season-standardized classifications of 25(OH)D and were support-
ed by risk estimates when 25(OH)D was modeled as a continuous
measure.
In addition to food and supplemental sources, vitamin D is
synthesized in the skin when exposed to ultraviolet B radiation
from sunlight, and hydroxylated in the liver to form 25(OH)D [1].
An additional hydroxylation in the kidney and other organs [1,18]
converts 25(OH)D to the active form 1,25-dihydroxyvitamin D
[1,25(OH)2D] via the 1-a-hydroxylase enzyme, which is also
expressed in the lung [18,19]. Potential anti-carcinogenic activity
of 1,25(OH)2D includes the promotion of cellular differentiation
and apoptosis, and the inhibition of cellular proliferation and
angiogenesis [1].
Ecologic studies have linked sunlight exposure with reduced
incidence and mortality of cancer at many sites, including lung
cancer [20,21] and lung cancer survival was better for patients
diagnosed in the summer or fall compared with the winter
[22,23]. The underlying biology for these observations has been
attributed to vitamin D [20,22,23]. In a study of early-stage non-
small cell lung cancer patients, higher circulating 25(OH)D [24],
specific vitamin D receptor (VDR) genetic variants [25], and high
vitamin D intakes combined with surgery in the summer [26]
Table 2. Association between serum 25(OH)D and risk of lung cancer, presented as season-specific quintiles, season-standardized
quintiles, and clinically pre-defined cutpoints, and stratified on season of blood collection.
1
Quintiles
12345P -trend
Season-Specific
2
Cases/Controls, N 95/101 120/100 108/100 71/100 106/99
Crude OR
3 (95% CI) 1.00 (reference) 1.29 (0.87–1.90) 1.16 (0.78–1.72) 0.75 (0.49–1.15) 1.16 (0.76–1.77) 0.58
Multivariate-adjusted OR
4 1.00 (reference) 1.28 (0.83–1.99) 1.20 (0.77–1.86) 0.83 (0.52–1.35) 1.08 (0.67–1.75) 0.58
Darker season
4 1.00 (reference) 1.28 (0.75–2.20) 0.91 (0.52–1.57) 0.58 (0.31–1.08) 0.77 (0.41–1.45) 0.05
Sunnier season
4 1.00 (reference) 1.46 (0.64–3.34) 2.44 (1.07–5.57) 1.89 (0.80–4.44) 1.81 (0.78–4.19) 0.24
Season-standardized
5
Cases/Controls, N 110/100 111/100 88/100 96/100 95/100
Crude OR
3 (95% CI) 1.00 (reference) 0.99 (0.69–1.44) 0.79 (0.53–1.18) 0.86 (0.58–1.28) 0.85 (0.57–1.27) 0.03
Multivariate-adjusted OR
4 1.00 (reference) 0.96 (0.64–1.45) 0.85 (0.54–1.33) 0.95 (0.61–1.48) 0.83 (0.53–1.31) 0.47
Darker season
4 1.00 (reference) 0.90 (0.53–1.52) 0.60 (0.32–1.10) 0.68 (0.38–1.21) 0.65 (0.37–1.14) 0.07
Sunnier season
4 1.00 (reference) 1.03 (0.51–2.10) 1.57 (0.74–3.33) 1.70 (0.78–3.73) 1.07 (0.45–2.51) 0.42
Categories of 25(OH)D (nmol/L)
Clinically pre-defined cutpoints ,25 25–,37.5 37.5–,50 50–,75 $75
Cases/Controls, N 176/151 106/120 93/98 93/102 32/29
Crude OR
3 (95% CI) 1.34 (0.91–1.99) 1.01 (0.68–1.50) 1.06 (0.71–1.60) 1.00 (reference)
6 1.22 (0.68–2.20) 0.29
Multivariate-adjusted OR
4 1.35 (0.87–2.10) 1.08 (0.70–1.69) 1.18 (0.74–1.87) 1.00 (reference) 1.23 (0.64–2.36) 0.35
Darker season
4 1.75 (0.98–3.13) 1.26 (0.68–2.33) 0.79 (0.40–1.55) 1.00 (reference) 1.07 (0.41–2.81) 0.01
Sunnier season
4 0.66 (0.29–1.49) 0.96 (0.46–1.97) 1.95 (0.96–3.98) 1.00 (reference) 1.25 (0.47–3.32) 0.21
Abbreviations: 25(OH)D=25-hydroxyvitamin D; CI=confidence interval; OR=odds ratio.
1Darker season (300 cases/300 controls)=November–April, Sunnier season (200 cases/200 controls)=May–October.
2Cutpoints for the season-specific quintiles were Q1: #16.8, Q2: .16.8 and #25.7, Q3: .25.7 and #37.1, Q4: .37.1 and #50.1, Q5: .50.1 nmol/L for the darker season
and Q1: #24.3, Q2: .24.3 and #35.0, Q3: .35.0 and #46.7, Q4: .46.7 and #57.8, Q5: .57.8 nmol/L for the sunnier season.
3Crude odds ratios are based on conditional logistic regression.
4Multivariate-adjusted odds ratios are conditioned on the matching factors and adjusted for smoking (#cigarettes/day and # years smoked), body mass index, serum
cholesterol, study supplementation group, and alcohol intake.
5Cutpoints for the season-standardized quintiles were Q1: #3.01, Q2: .3.01 and #3.38, Q3: .3.38 and #3.65, Q4: .3.65 and #3.94, Q5: .3.95 residual units.
6The referent group for the clinically pre-defined cutpoints is 50–,75 nmol/L. Data using the lowest category as the referent are reported in the text.
doi:10.1371/journal.pone.0020796.t002
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not circulating 25(OH)D, were associated with improved survival
in advanced non-small cell lung cancer patients [27]. However, in
an updated analysis of the NHANES III Study, higher 25(OH)D
was associated with an increased risk of lung cancer mortality
among men (RR=1.87, 95% CI 1.04–3.34, p-trend=0.03) [4],
and in the only other prospective study of circulating vitamin D
and lung cancer risk, which reported 25(OH)D values similar to
those in the current study, no overall association was observed
based on 122 cases [5]. The latter cohort included mainly non-
smokers (58% of men and 81% of women), with no reported
effect modification by smoking status or season of blood
collection, but an inverse association was observed between
25(OH)D and lung cancer risk in women and subjects younger
than 50 years [5].
While some evidence suggests a possible inverse association
between 25(OH)D and colorectal cancer risk, the data for breast
and prostate cancers are less conclusive [1,2]. In addition, a
recent pooling project of over 5,000 cancer cases suggested no
benefit of higher circulating 25(OH)D for risk of non-Hodgkin
lymphoma, or endometrial, ovarian, upper gastrointestinal, or
kidney cancers, and possible harm for pancreatic cancer [28–33].
By contrast, higher serum 25(OH)D concentrations were
associated with reduced risk of bladder cancer in the ATBC
Study [34], suggesting that it is possible to detect cancer
associations within the range of 25(OH)D concentrations
observed in ATBC. The current study is one of only a few to
examine 25(OH)D and lung cancer risk.
We used several approaches to account for seasonal variation
in 25(OH)D concentrations because a simulation study indicat-
ed that results could be biased either toward or away from the
null if seasonal variation was not properly considered [35]. We
selected an equal number of cases based on month of blood
collection, with controls matchedw i t h i n3 0d a y s .A n a l y s e sw e r e
conducted using season-specific and season-standardized
25(OH)D quintiles, and were stratified on season, the latter of
which indicated that 25(OH)D may be inversely associated with
lung cancer risk among subjects with blood collected during the
darker months. Circulating 25(OH)D is considered to best
reflect vitamin D status when measured in the winter [1], and in
a twin study, genetic factors explained variability of 25(OH)D
status only when measured in the winter [36]. Therefore, the
inverse association we noted during the darker months could
reflect the use of a more accurate measure of usual, chronic,
vitamin D status that is not influenced by episodic sun exposure
in summer. Alternatively, maintaining higher vitamin D status
during the longer period of winter months in higher latitudes
may be biologically important for the vitamin D-cancer
association; Vieth has hypothesized that sharp declines in serum
25(OH)D in the winter and a lag in the compensating response
of cellular hydroxylases involved in vitamin D metabolism (e.g.,
CYP24 and CYP27B1) could be detrimental in terms of cancer
risk [37]. This association could also simply be due to chance
a n ds h o u l db ee x a m i n e di no t h e rs t u d i e s .
The prospective design of the current study, with up to 20
years of follow-up, reduces any potential for an effect of cancer on
the 25(OH)D concentrations. All participants were current
smokers at baseline, but as no apparent confounding by smoking
duration or intensity was observed, and 25(OH)D was not
correlated with any of our measures of smoking, any effects due
to residual confounding from smoking are expected to be
minimal. Given that smoking is such a strong risk factor for lung
cancer, however, it is important to define additional lung cancer
risk factors in the context of smoking. Circulating 25(OH)D
incorporates the contributions of dietary and supplemental
vitamin D intake, as well as vitamin D due to sun exposure,
and is considered the accepted biomarker of vitamin D status [1].
Thus, 25(OH)D more accurately represents vitamin D status than
proxy measures such as latitude, sun exposure, dietary intake, or
season of diagnosis.
Vitamin D status in the study population was generally quite
low (median=35.0 nmol/L among controls) due to limited
vitamin D synthesis that occurs at high latitudes in the winter
months [1], few study blood collections in the peak summer
months, and because vitamin D supplement use was uncommon
in this population. It is unclear whether inverse associations
would be more evident at higher 25(OH)D concentrations. Only
one measurement of 25(OH)D was used to represent individual
long-term vitamin D exposure; however, 25(OH)D has been
correlated in samples collected from the same individuals 3–14
years apart [38–40]. Since our study subjects were 50–69 year old
men, we were unable to re-examine the previous findings of an
inverse association among women and subjects younger than 50
years [5] and our findings may not be generalizable to younger,
female, and/or non-smoking populations.
In summary, in the overall analysis of this prospective study,
25(OH)D was not associated with lung cancer risk using the
season-specific, season-standardized, or pre-defined classifications
of 25(OH)D. However, in analyses stratified on season of blood
collection, an inverse association between 25(OH)D status and
lung cancer risk was suggested when blood was collected during
the darker months of the year, a time when skin synthesis of
25(OH)D is reduced. Future studies of vitamin D status and lung
cancer risk should specifically examine associations stratified by
season of blood collection.
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